Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a termination agreement with Sorbie Bornholm LP and Sorbie Investments LLP to end a performance-based funding arrangement originally announced on July 29, 2026. The move, disclosed in a press release disseminated on behalf of Onco-Innovations Limited, will result in Sorbie returning an aggregate of 5,380,683 common shares for cancellation. That total comprises 2,761,635 shares held by Sorbie Bornholm and 2,619,048 shares held by Sorbie Investments.
Under the terms of the agreement, Sorbie Bornholm will receive the remaining credit support corresponding to C$4,444,444, while Onco-Innovations will relinquish its rights to further payments under the arrangement. The transaction will not require any additional cash payment by the company. Additionally, Sorbie Investments will waive its right to receive 2.25 million additional common share purchase warrants, eliminating Onco-Innovations’ obligation to issue those warrants.
The termination remains subject to customary closing conditions, including approval from Cboe Canada, and will take effect on a closing date agreed upon by the parties. For investors seeking the full details, the complete press release is available at https://ibn.fm/nx0ZV.
The cancellation of more than 5.38 million shares represents a notable reduction in Onco-Innovations’ issued capital, which could be accretive to existing shareholders by improving per-share metrics such as earnings and book value. The elimination of 2.25 million warrants also removes potential future dilution, further simplifying the company’s capital structure. Because no cash outlay is required, the company retains its financial resources for other priorities.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company holds an exclusive worldwide licence to patented technology directed to the therapeutic inhibition of PNKP, a novel clinical target in DNA damage response. This scientific focus positions Onco-Innovations in the growing field of DNA damage response therapeutics, which aims to exploit cancer cells’ vulnerabilities in repairing their DNA.
For ongoing updates and news about Onco-Innovations, the company maintains a newsroom at https://ibn.fm/ONNVF. The announcement was distributed through InvestorWire, a wire service that offers unlimited words on domestic releases, as highlighted in its comparison chart, and provides complimentary press release enhancement. InvestorWire is part of the InvestorBrandNetwork, which leverages over 50 brands to provide follow-up coverage. More information about InvestorWire’s services is available at https://www.investorwire.com.
